Omega Therapeutics, Inc.
OMGAQ
$0.0381
-$0.0069-15.33%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 214.32% | 181.16% | 357.36% | 34.56% | 39.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 214.32% | 181.16% | 357.36% | 34.56% | 39.66% |
| Cost of Revenue | -25.58% | -57.82% | -23.27% | -53.09% | -36.10% |
| Gross Profit | 42.66% | 66.30% | 33.31% | 55.63% | 38.47% |
| SG&A Expenses | -13.39% | -0.88% | 18.47% | 67.25% | 60.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.81% | -40.78% | -13.38% | -31.59% | -10.71% |
| Operating Income | 28.31% | 46.24% | 20.79% | 33.16% | 11.86% |
| Income Before Tax | 26.09% | 45.08% | 20.37% | 34.43% | 13.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.09% | 45.08% | 20.37% | 34.43% | 13.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.09% | 45.08% | 20.37% | 34.43% | 13.76% |
| EBIT | 28.31% | 46.24% | 20.79% | 33.16% | 11.86% |
| EBITDA | 28.84% | 47.10% | 21.37% | 33.70% | 12.23% |
| EPS Basic | 26.12% | 45.17% | 26.90% | 43.04% | 25.15% |
| Normalized Basic EPS | 26.13% | 45.15% | 26.91% | 43.05% | 25.14% |
| EPS Diluted | 26.12% | 44.44% | 26.90% | 43.04% | 25.15% |
| Normalized Diluted EPS | 26.13% | 45.15% | 26.91% | 43.05% | 25.14% |
| Average Basic Shares Outstanding | 0.03% | 0.14% | 8.93% | 15.13% | 15.22% |
| Average Diluted Shares Outstanding | 0.03% | 0.14% | 8.93% | 15.13% | 15.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |